- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.03. | Guggenheim reiterates Neumora stock rating on pipeline progress | 20 | Investing.com | ||
| 30.03. | Stifel reiterates Neumora Therapeutics stock Hold rating at $3 | 3 | Investing.com | ||
| NEUMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.03. | Stifel bestätigt 'Hold'-Rating für Neumora Therapeutics mit Kursziel von 3 US-Dollar | 4 | Investing.com Deutsch | ||
| 30.03. | Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 | 11 | Seeking Alpha | ||
| 30.03. | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 147 | GlobeNewswire (Europe) | New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of... ► Artikel lesen | |
| 30.03. | Neumora Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.03. | Neumora Therapeutics, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 30.03. | Neumora Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts | 9 | Benzinga.com | ||
| 16.03. | Neumora Therapeutics, Inc.: Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 | 9 | GlobeNewswire (USA) | ||
| 04.03. | Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 | 9 | Insider Monkey | ||
| 17.02. | Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment | 12 | Benzinga.com | ||
| 11.02. | Neumora Therapeutics, Inc. - 8-K, Current Report | 27 | SEC Filings | ||
| 04.02. | Neumora Therapeutics, Inc.: Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 | 5 | GlobeNewswire (USA) | ||
| 12.01. | Neumora Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 12.01. | Leerink Partners initiates coverage on Neumora stock with Outperform rating | 10 | Investing.com | ||
| 07.01. | Mizuho bestätigt Outperform-Rating für Neumora nach starkem Kurssprung | 15 | Investing.com Deutsch | ||
| 07.01. | Mizuho reiterates Outperform rating on Neumora Therapeutics stock | 2 | Investing.com | ||
| 05.01. | Neumora's Alzheimer's Agitation Drug Shows Early Promise | 11 | Benzinga.com | ||
| 05.01. | Mizuho raises Neumora Therapeutics stock price target on positive trial data | 7 | Investing.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,55 | +0,11 % | BioNTech, Shell, Zweistellige Inflationsrate? Das 4investors.de-Weekend | Welche Themen haben Anleger bewegt? Hier sind die 4investors.de-Berichte vom Wochenende von BioNTech über Shell bis zu einer aktuellen Marktanalyse mit Fokus auf die Folgen des Iran-Kriegs. BioNTech-Wirkstoff... ► Artikel lesen | |
| MODERNA | 45,690 | +0,12 % | Moderna - MRNA: Impfstoff-Aktie mit mega-starkem Comeback! | + 100 Prozent in 6 Monaten! mrRNA-Impfstoffe gegen Krebs, Grippe & RSV bei Moderna in der Pipeline! Neue Rallye trotz US-Gesundheitsminister Robert F. Kennedy? Moderna (MRNA) - ISIN US60770K1079 Rückblick:... ► Artikel lesen | |
| AMGEN | 301,95 | +0,03 % | Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy | ||
| NOVAVAX | 7,430 | -1,07 % | Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In | ||
| BIOGEN | 149,42 | -0,84 % | Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks | ||
| ILLUMINA | 114,66 | +0,35 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,340 | +0,11 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| VIKING THERAPEUTICS | 29,950 | +0,17 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| MAINZ BIOMED | 0,487 | -3,45 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 12,640 | -0,47 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 47,510 | +0,07 % | Here's What TD Cowen Thinks About Tempus AI Inc (TEM) Stock | ||
| BIOCRYST PHARMACEUTICALS | 8,100 | +0,40 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2026 Financial Results on May 6 | ||
| BIOMARIN PHARMACEUTICAL | 45,660 | -2,48 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,960 | -1,86 % | H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target | ||
| EXELIXIS | 38,160 | +0,03 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen |
NEUMORA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,155 Euro und damit +7,75 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUMORA THERAPEUTICS INC finden Sie auf Wallstreet Online.